A STUDY TO EVALUATE THE EFFECTS OF PYRIDOSTIGMINE ON BLOOD GLUCOSE LEVELS IN DEXAMETHASONE INDUCED DIABETIC ALBINO RATS.
Main Article Content
Keywords
Hyperglycaemia, Pyridostigmine, Metformin
Abstract
Background: Type 2 diabetes mellitus (T2DM) is a chronic and progressive disease. It is characterised by the presence of both insulin resistance and relative insulin deficiency. At present, the management of T2DM include diet, lifestyle modification and oral hypoglycaemic drugs. Acetylcholine stimulates the release of insulin and pancreatic polypeptide (PP) from pancreas. PP inhibits gastric emptying rate, decreases food intake and enhances insulin sensitivity. Pyridostigmine acts by increasing the availability of acetylcholine at the cholinergic receptors.
Methods: Thirty adult Wistar albino rats weighing 200-350g, of either sex were taken into study and divided into 5 groups of 6 animals each. 1.Normal control 2. Dexamethasone control 3. Pyridostigmine control 4. Metformin+Dexamethasone 5.Pyridostigmine+Dexamethasone. Distilled water was given per orally to group1 for 7 days and group2 for initial 4 days. Dexamethasone was given to group 2, 4 and 5 intraperitoneally for the last 3 days. Metformin to group 4 and pyridostigmine to group 3 and 5 were given per orally. Oral glucose tolerance test was performed on 5th and 7th day at 0, 60 and 120 min time interval using a glucometer.
Results: Both metformin and pyridostigmine showed fall in blood glucose levels. But metformin showed reduced levels at all the time intervals compared to pyridostigmine.
Conclusions: Although pyridostigmine showed hypoglycaemic activity in dexamethasone induced hyperglycaemia in rats but metformin showed better antihyperglycemic effect
References
2. R Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, Dunning T, et al. IDF Diabetes Atlas. 6th ed., Brussels, Belgium: International Diabetes Federation; 2013.
3. Nicholson G and Hall G.M. Diabetes mellitus: new drugs for a new epidemic. British Journal of Anaesthesia. 2011;107(1):65–73.
4. Andersen JB, Engeland A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol. 2010;17:1445–1450.
5. Maselli RA, Henderson JD, Ng J, Follette D, Graves G, Wilson B W. Protection of human muscle acetylcholinesterase from soman by pyridostigmine bromide. Muscle Nerve. 2011;43:591–595.
6. Tan Q, Hu N, Liu G, et al. Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability. Arch Pharm Res. 2012;35:499–508.
7. JurajKoska, Angelo DelParigi, Barbora de Courten, Christian Weyer, and P Antonio Tataranni. Pancreatic Polypeptide Is Involved in the Regulation of Body Weight in Pima Indian Male Subjects. Diabetes. 2004;53:3092-96.
8. Atoosa Rabiee, Panagis Galiatsatos, Rocio Salas-Carrillo, Michael J Thompson, Dana K. Andersen, Dariush Elahi. Pancreatic Polypeptide Administration Enhances Insulin Sensitivity and Reduces the Insulin Requirement of Patients on Insulin Pump Therapy. Journal of Diabetes Science and Technology. 2011;5(6):1521-28.
9. D Gautam, SJ Han, A Duttaroy, D Mears, F Hamdan, JH Li, et al. Role of the M3 muscarinic acetylcholine receptor in β-cell function and glucose homeostasis. Diabetes, Obesity and Metabolism. 2007;9(2):158–69.
10. Daniela Billups, Brian Billups, RA John Challiss, and Stefan R. Nahorski. Modulation of Gq-Protein-Coupled Inositol Trisphosphate and Ca2 Signaling by the Membrane Potential. The Journal of Neuroscience. 2006;26(39):9983–95.
11. Amoghimath S, Suresha RN, Jayanthi MK, et al. To Evaluate the Effect of Edrophonium on Blood Glucose Levels in Euglycemic Albino Rats Through OGTT. J Clin Diagn Res. 2015;9(1):FF04-7.
12. Bikash Medhi, Ajay Prakash. Introduction to experimental pharmacology. In: BikashMedhi, editors. Practical manual of experimental and clinical pharmacology. New Delhi: Jaypee; 2010.p. 23-25.
13. M.S. Muntzel, I. Hamidou, S. Barrett, Metformin attenuates salt-induced hypertension in spontaneously hypertensive rats, Hypertension 33 (1999) 1135–1140.
14. Fu Z, Gilbert ER, Liu D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr Diabetes Rev. 2013;9(1):25-53.
15. Abdul-Ghani MA, Matsuda M, Jani R, et al. The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab. 2008;295(2):E401-6
16. Mitsuhisa Komatsu, Yoshihiko Sato, Satoko Yamada, Keishi Yamauchi, Kiyoshi Hashizume, and Toru Aizawa. Triggering of Insulin Release by a Combination of cAMP Signal and Nutrients An ATP-Sensitive K Channel–Independent Phenomenon. Diabetes. 2002;51(1):29-32.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Raghavendra Belavatagi
Assistant professor, Department of Pharmacology, Dr Chandramma dayanand sagar Institute of Medical Education and Research, A unit of Dayanand Sagar University, Bengaluru, Karnataka, India
Dr Ravichandra Volabailu
Professor, Department of Pharmacology, K.S. Hegde Medical Academy, Nitte (Deemed to be University), Mangaluru, Karnataka, India
Dr Anusha SJ
3Assistant professor, Department of Pharmacology, Dr Chandramma dayanand sagar Institute of Medical Education and Research, A unit of Dayanand Sagar University, Bengaluru, Karnataka, India